Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 5, 1996, Pages 421-433

  Nagai, Naomi ^a   Kawakubo, Takashi ^a   Kaneko, Fumiyo ^b   Ishii, Mika ^b   Shinohara, Raito ^a   Saito, Yukihisa ^a   Shimamura, Hideo ^b   Ohnishi, Akihiro ^b   Ogata, Hiroyasu ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dextromethorphan; Free and conjugated metabolites; Japanese population; Pharmacokinetics; Phenotyping

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN;

ADULT; ARTICLE; DOSE TIME EFFECT RELATION; DRUG DEGRADATION; DRUG EXCRETION; DRUG OXIDATION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; RACE DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; ANTITUSSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; HUMANS; JAPAN; MALE; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM, GENETIC; REFERENCE STANDARDS;

EID: 0029682520     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-081x(199607)17:5<421::aid-bdd421>3.0.co;2-9     Document Type: Article

References (21)

1. A. Kupfer, B. Schmid, R. Preisig and G. Pfaff, Dextromethorphan as a safe probe for debrisoquin hydroxylation polymorphism. Lancet, 2, 517-518 (1984).
2. B. Schmid, J. Bircher, R. Preisig and A. Küpfer, Polymorphic dextromethorphan metabolism: co-segregation of oxidative 0-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38, 618-624 (1985).
3. A. Kupfer, B. Schmid and G. Pfaff, Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica, 16, 421-433 (1986).
4. D. Larrey, G. Amouyal, M. Tinel, P. Letteron, A. Berson, G. Labbe and D. Pessayre, Polymorphism of dextromethorphan oxidation in a French population. Br. J. clin. Pharmac., 24, 676-679 (1987).
5. R. J. Guttendorf, M. Britto, R. A. Blouin, T. S. Foster, W. John, K. A. Pittman and P. J. Wedlund, Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br. J. din. Pharmac., 29, 373-380 (1990).
6. P. S. Marshall, R. J. Straka and K. Johnson, Determination of dextromethorphan and its O-demethylated metabolite from urine. Ther. Drug Monit., 14, 402-407 (1992).
7. T. K. Henthorn, J. Benitez, M. J. Avram, C. Martinez, A. Llerena, J. Cobaleda, T. C. Krejcie and R. D. Gibbons, Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin. Pharmacol. Ther., 45, 328-333 (1989).
8. K. Nakamura, F. Goto, W. A. Ray, C. B. McAllister, E. Jacqz, G. R. Wilkinson and R. A. Branch, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther., 38, 402-08 (1985).
9. T. Ishizaki, M. Eichelbaum, Y. Horai, K. Hashimoto, K. Chiba and H. J. Dengler, Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br. J. din. Pharmac., 23, 482485 (1987).
10. Y. Horai, T. Ishizaki and K. Ishikawa, Metoprolol oxidation in a Japanese population: evidence for only one poor metabolizer among 262 subjects. Br. J. din. Pharmac., 26, 807808 (1988).
11. G. Pfaff, P. Briegel and I. Lamprecht, Interindividual variation in the metabolism of dextromethorphan. Int. J. Pharm., 14, 173-189 (1983).
12. S. J. Vetticaden, B. E. Cabana, V. K. Prasad, E. D. Purich, J. H. J. Jonkman, R. Zeeuw, L. Ball, L. J. Leeson and R. L. Braun, Phenotypic differences in dextromethorphan metabolism. Pharm. Res., 6, 13-19 (1989).
13. E. J. Aigrain, C. F. Brentano and T. Crosteil, CYP2D6- and CYP3A- dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204 (1993).
14. J. C. Duché, V. Q. Ferrer, J. Barre, M. Mesangeau and J. P. Tillement, Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int. J. Clin. Pharmacol. Ther. Toxicol., 31, 392-398 (1993).
15. T. East and D. Dye, Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr., 338, 99-112 (1985).
16. M. Silvasti, P. Karttunen, H. Tukiainen, P. Kokkonen, U. Hänninen and S. Nykänen, Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol., 25, 493-497 (1987).
17. M. Takebe, A. Junichi, Y. Akifumi, T. Munetetsu and K. Susumu, Pharmacokinetic analysis and graphies for clinical pharmacology. Japan. J. Clin. Pharmacol. Ther., 20, 139-140 (1989).
18. H. H. Zhou, J. R. Sheller, H. Nu, M. Wood and A. J. J. Wood, Ethnie differences in response to morphine. Clin. Pharmacol. Ther., 54, 507-513 (1993).
19. H. Takahashi, H. Ogata and R. Warabioka, Decreased absorption as a possible cause for thé lower bioavailability of a sustained-release propranolol. J. Pharnt. Sei., 79, 212-215 (1990).
20. M. Eichelbaum, Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin. Pharmacokinet., 7, 1-22 (1982).
21. K. Brosen, Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin. Pharmacokinet., 18, 220-239 (1990).